Logo for the European Board for Accreditation of Continuing Education for Health Professionals

This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

Laura Michaelis

Welcome and introductions

Haifa Kathrin Al-Ali

MDM2 inhibition in MF

Haifa Kathrin Al-Ali

Overview of the navtemadlin trials (NCT03662126)

  • Phase II design
  • Phase III design (BOREAS trial)
Haifa Kathrin Al-Ali

Key phase II efficacy/safety findings

Laura MichaelisHaifa Kathrin Al-Ali

What do the navtemadlin trials mean for clinical practice?

Laura Michaelis


In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Learning objectives

Following this event, participants will be able to:

  • Describe novel therapeutic targets in MPN
  • Explain the mechanisms of action of MDM2 inhibitors in MPN
  • State the efficacy and safety data for navtemadlin in MPN
  • Explain the role of navtemadlin in the MPN therapeutic landscape

Registration form

Registration is free. Please complete the form and submit to register.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy